tiprankstipranks
Trending News
More News >

Traws Pharma Publishes Promising Phase 2 Study Results

Story Highlights
  • Traws Pharma focuses on oncology programs, particularly rigosertib and narazaciclib.
  • A Phase 2 study showed rigosertib’s 80% response rate in treating advanced squamous cell carcinoma.
  • Looking for the best stocks to buy? Follow the recommendations of top-performing analysts.
Traws Pharma Publishes Promising Phase 2 Study Results

Don’t Miss TipRanks’ Half-Year Sale

An announcement from Traws Pharma ( (TRAW) ) is now available.

On June 3, 2025, Traws Pharma announced the publication of clinical efficacy data for patients with recessive dystrophic epidermolysis bullosa associated with locally advanced or metastatic squamous cell carcinoma treated with rigosertib. The Phase 2 study showed an overall response rate of 80% and complete responses in 50% of evaluable patients, highlighting significant potential for rigosertib in addressing this high unmet medical need.

The most recent analyst rating on (TRAW) stock is a Buy with a $7.00 price target. To see the full list of analyst forecasts on Traws Pharma stock, see the TRAW Stock Forecast page.

Spark’s Take on TRAW Stock

According to Spark, TipRanks’ AI Analyst, TRAW is a Underperform.

Traws Pharma’s overall stock score is low due to significant financial challenges and bearish technical indicators. However, recent corporate events, including positive trial data and new financing, provide a glimmer of hope for future improvements, albeit with high risk.

To see Spark’s full report on TRAW stock, click here.

More about Traws Pharma

Traws Pharma, Inc. operates in the pharmaceutical industry, focusing on oncology programs. The company is involved in the development of treatments for various cancers, with a particular emphasis on its legacy oncology programs, rigosertib and narazaciclib.

Average Trading Volume: 99,356

Technical Sentiment Signal: Sell

Current Market Cap: $7.9M

Learn more about TRAW stock on TipRanks’ Stock Analysis page.

Disclaimer & DisclosureReport an Issue

Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App
1